Related Experiment Video
Updated: Jul 9, 2026
10:52
Differentiation and Characterization of Osteoclasts from Human Induced Pluripotent Stem Cells
Published on: March 22, 2024
Single-cell transcriptomics identifies CD36 as a negative regulator of osteogenic differentiation in murine
Weibin Wang1, Xinyou Han1, Qingsong Fu1
1Department of Orthopaedic Trauma, Ningbo No. 2 Hospital, Wenzhou Medical University, No. 41, Xibei Street, Haishu District, 315010 Ningbo, China.
Joint Bone Spine
|July 7, 2026
Summary
CD36 negatively regulates bone formation by impairing osteogenic differentiation of bone marrow mesenchymal stem cells (BM-MSCs). Targeting CD36 may offer a new therapeutic approach for osteoporosis.
Area of Science:
- Stem cell biology
- Bone biology
- Molecular medicine
Background:
- Osteoporosis involves impaired osteogenic differentiation of bone marrow mesenchymal stem cells (BM-MSCs).
- Molecular mechanisms underlying this impairment in murine models are not fully understood.
Purpose of the Study:
- Identify key regulators of BM-MSC osteogenic differentiation in murine osteoporosis using single-cell transcriptomics.
- Validate the in vivo functional role of identified candidates.
Main Methods:
- Single-cell RNA sequencing of murine osteoporosis and osteoarthritis samples.
- Identification of differentially expressed genes and selection of CD36 via GO-KEGG analysis.
- In vivo validation using adeno-associated virus-mediated CD36 knockdown in an ovariectomy mouse model, assessing bone microarchitecture and osteogenic capacity.
Main Results:
- CD36 was significantly upregulated in BM-MSCs from osteoporotic murine samples.
- CD36-positive BM-MSCs showed enrichment in peroxisome proliferator-activated receptor signaling and extracellular matrix-receptor interaction pathways.
- CD36 knockdown in ovariectomized mice restored bone parameters and increased osteoprogenitor numbers.
Conclusions:
- CD36 acts as a negative regulator of osteogenic differentiation in murine BM-MSCs.
- Targeting CD36 could be a therapeutic strategy for osteoporosis by rebalancing osteogenic and adipogenic processes in bone marrow.
